SITC seeks applications for two fellowships

Society for Immunotherapy of Cancer announces 2026 annual award recipients

The Society for Immunotherapy of Cancer announced the recipients of its 2026 Annual Awards, recognizing individuals whose exceptional leadership, scientific achievements and service have helped advance the field of cancer immunotherapy.

August 07, 2026

Vol.52 No.31

Clinical Trials & Tribulations

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

The recent retraction of the LungTIME-C01 randomized trial evaluating chrono-modulated immunotherapy in non-small cell lung cancer has ignited a vigorous debate regarding the promise of cancer chronotherapy.

July 31, 2026

Vol.52 No.30

By Zachary S. Buchwald and Michael C. Lowe

News Analysis

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

On Feb. 2, Nature Medicine published the results of a large, randomized, prospective clinical trial in the nascent and some say, fringe, field of chrono-oncology—the study of how natural biological rhythms might impact cancer outcomes.

July 10, 2026

Vol.52 No.27

By Jacquelyn Cobb

AI in action: MANAscore tool moves closer to clinic

One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.

June 05, 2026

Vol.52 No.22

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

Despite major advances in immunotherapy, most patients with hepatocellular carcinoma fail to respond to current immune checkpoint inhibitors.

May 15, 2026

Vol.52 No.19

By Dan G. Duda

Clinical Roundup

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first-in-the-world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment.

May 08, 2026

Vol.52 No.18

SITC seeks applications for two fellowships

YOU MAY BE INTERESTED IN

Society for Immunotherapy of Cancer announces 2026 annual award recipients

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

AI in action: MANAscore tool moves closer to clinic

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Renew today!

Subscriber content

Never miss an issue!

Login

SITC seeks applications for two fellowships

YOU MAY BE INTERESTED IN

Society for Immunotherapy of Cancer announces 2026 annual award recipients

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

AI in action: MANAscore tool moves closer to clinic

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Never miss an issue!

Login

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.